12/11
09:51 am
enlv
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $13.00 price target on the stock.
Low
Report
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $13.00 price target on the stock.
12/11
08:40 am
enlv
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis [Yahoo! Finance]
Medium
Report
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis [Yahoo! Finance]
12/11
08:30 am
enlv
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
Low
Report
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
12/4
11:48 am
enlv
Trump's crypto advocacy steers businesses away from traditional treasury assets [Yahoo! Finance Canada]
High
Report
Trump's crypto advocacy steers businesses away from traditional treasury assets [Yahoo! Finance Canada]
12/4
11:42 am
enlv
Trump's crypto advocacy steers businesses away from traditional treasury assets [Yahoo! Finance Canada]
Medium
Report
Trump's crypto advocacy steers businesses away from traditional treasury assets [Yahoo! Finance Canada]
12/4
11:41 am
enlv
Trump's crypto advocacy steers businesses away from traditional treasury assets [Yahoo! Finance]
Medium
Report
Trump's crypto advocacy steers businesses away from traditional treasury assets [Yahoo! Finance]
12/3
09:48 am
enlv
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $13.00 price target on the stock.
Medium
Report
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $13.00 price target on the stock.
12/3
08:30 am
enlv
Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
High
Report
Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
11/26
10:15 am
enlv
Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3
Medium
Report
Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3
11/20
08:00 am
enlv
Enlivex Adopts Bitcoin Treasury Reserve Strategy
High
Report
Enlivex Adopts Bitcoin Treasury Reserve Strategy
11/14
08:00 am
enlv
Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis
Medium
Report
Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis
11/12
08:00 am
enlv
Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
Low
Report
Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
10/30
08:00 am
enlv
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis
Medium
Report
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis
9/27
08:07 am
enlv
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Medium
Report
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.